Utilizing a Promotora Model for Rural Adult Hispanics Diagnosed With Metabolic Syndrome: A Clinical Trial (FMRIMetSynd)

The study aims are to test whether the use of promotoras significantly impacts the health attitudes, health seeking behaviors, and patient confidence in self-managing health of rural Hispanic adults who have been diagnosed with metabolic syndrome. Specifically, the study is designed to address four areas of inquiry: 1) identification of patient attitudes involving: a) trust in medical providers and in the health care system, b) procedural fairness in treatment, c) provider and patient communication patterns, d) potential cultural bias in treatment, and e) healthy lifestyle behavior adoption/maintenance, 2) selected clinical indicators of metabolic syndrome (blood pressure, height/weight/BMI, blood glucose, hemoglobin A1c, and cholesterol), 3) the cultural competence of medical providers from the perspective of both the provider and the patient, and 4) patient self-management confidence scores.

Study Overview

• Status: Withdrawn
• Conditions: Metabolic Syndrome
• Intervention / Treatment: Behavioral: Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count

Detailed Description

The following research questions will be investigated in this study:

1. For adult rural Hispanic patients who have been diagnosed with metabolic syndrome, does adding the services of a promotora to a standard care model significantly change the metrics associated with metabolic syndrome to a greater extent than a standard care model only?
2. For adult rural Hispanic patients who have been diagnosed with metabolic syndrome, does adding the services of a promotora to a standard care model significantly change the attitude of trust in medical providers and the health care system to a greater extent than a standard care model only?
3. For adult rural Hispanic patients who have been diagnosed with metabolic syndrome, does adding the services of a promotora to a standard care model significantly change the attitudes associated with comfort with seeking care in the health care system to a greater extent than a standard care model only?
4. For adult rural Hispanic patients who have been diagnosed with metabolic syndrome, does adding the services of a promotora to a standard care model significantly change the perception of cultural bias in regard to treatment as compared with patients using the standard care model only?
5. For adult rural Hispanic patients who have been diagnosed with metabolic syndrome, does adding the services of a promotora to a standard care model significantly change the attitudes associated with feelings of procedural fairness in health care treatment to a greater extent than a standard care model only?
6. For adult rural Hispanic patients who have been diagnosed with metabolic syndrome, does adding the services of a promotora to a standard care model significantly change the Patient Activation Measure (PAM) score over time as compared with patients utilizing only the standard care model?
7. For adult rural Hispanic patients who have been diagnosed with metabolic syndrome, does adding the services of a promotora to a standard care model significantly change the doctor-patient communication score over time as compared with patients utilizing only the standard care model?
8. For rural Hispanic patients who have been diagnosed with metabolic syndrome, does adding the services of a promotora to a standard care model significantly change the perception of the cultural competence of providers as compared with patients experiencing the standard care model only?

The proposed study utilizes a randomized clinical trial design to assess the efficacy of combining community health worker/ promotora services plus standard clinical care versus a standard clinical care model only for rural Hispanic patients diagnosed with metabolic syndrome. This design has been selected because: 1) it best protects against possible confounding, 2) there are no ethical issues with the study as all participants receive at a minimum the current standard of care for metabolic syndrome, 3) three years is enough time to assess results, and 4) sufficient staffing is available. In order to answer the research questions posed earlier, primary data must be collected since a design that analyzes secondary data is not sufficient in this instance.

Patients will be identified from three primary care clinics in Southern Idaho where they receive care. The clinics are located in Caldwell, Nampa, and Jerome, Idaho. Caldwell has a population of 47,000 (50.6% female) with 35% being Hispanic and 26% speaking Spanish as their primary language. Nampa has a population of 81,000 (51% female) with 23% being Hispanic and 17% of homes not having English as their primary language. Jerome has a population of 11,000 (49.5% female) with 34% being Hispanic and approximately 24% of the homes with Spanish as the primary language spoken.32 The Family Medicine Residency of Idaho (FMRI) has two Rural Training Track (RTT) programs that will be participating, one in Caldwell and one in Jerome (about 130 miles east of Caldwell). A third site will be a clinic (35% of patients are Hispanic) in rural Nampa, a community located about 15 miles outside of Boise. Each of these rural clinics sees between 1,000 (Nampa and Jerome) and 1,800 (Caldwell) unduplicated adult Hispanic patients per year, and an estimated 10-20% have metabolic syndrome or are at extreme risk for developing this condition. After a review of medical records, those patients identified with metabolic syndrome will be sent a letter inviting participation in the study. Patients from outside the clinics will also be eligible to participate by being notified of the opportunity through community advertising on Spanish language radio and in churches, restaurants, and grocery stores frequented by members of the Hispanic community. A patient recruitment coordinator will be employed for this purpose, and he/she will continue to recruit until the number of patients needed to reach an adequate sample size and who agree to participate is reached. No more than one patient per family will be allowed to participate in the study. The Caldwell Clinic will seek to have 128 patients in each of the intervention and control groups (four cohorts of 32 in each of the intervention and control groups). Each of the other two clinics will have a goal of 60 patients in each of the groups (three cohorts of 20 in each of the intervention and control groups). The cumulative number of 248 per group (sum of total enrollments from each clinic) is to allow for a 10-12% attrition rate throughout the study timeframe and still retain statistical power to detect differences that might exist between groups. If the 10% attrition occurs, each group would still have an "n" of 225 which is the value used to determine the statistical power in the analysis subsection of this plan. A chart in the appendices illustrates the study sites, cohort sizes, and dates of data collection. Although discussed in detail in Section Four, only those patients meeting the inclusion criteria and who consent to participate will be included in the study.

All participants in this study will be adult rural residing patients of Hispanic ethnicity diagnosed with metabolic syndrome. Patients from each clinic will be randomized into a control group (total three clinic n = 248) and an intervention group (total three clinic n = 248) with the intervention group receiving education from a promotora in addition to the standard treatment and the control group receiving the standard treatment protocol. All patients will receive annual physical exams and appropriate lab tests (lab tests every six months) and regular MD follow up. At time of introduction into the study and at six month intervals for a period of one year, all participants will complete a patient activation measure (PAM) and other qualitative attitude measures that will be described in more detail later in this section. Initiation of the study will be staggered with the Caldwell clinic starting in January 2014 and the other two clinics starting in April of 2015. Again, please see the appendices for a detailed study plan chart complete with timelines. The use of multiple clinics helps minimize (or at least allows for control for) the potential influence of clinic environment and provider effects and enables better control for possible cohort and history effects.

Using the Caldwell clinic as an example, each of the two promotoras will work with 16 patients over a three month period. During this timeframe, they will conduct four home education visits with each patient and four group sessions with their entire 16 member cohort. At the conclusion of the first three months, a new 16 patient cohort/promotora will be started with new intervention patients. This three month intense contact sequence for Caldwell patients will be repeated over four cycles until all 128 intervention patients have experienced promotora exposure. Following their three month intense promotora exposure all intervention patients will experience once monthly large group sessions with a promotora for a total of nine months and will complete qualitative questionnaires and laboratory tests at six month intervals until one year from their start date arrives. After a patient's one year anniversary of beginning the study protocol, the study will end for that person. Each intervention cohort will be accompanied by a control group of patients equal in number. The one year timeframe for each clinic helps reduce the chances of an elevated drop-out rate.

This pattern will repeat itself in year two with the Nampa clinic and the Jerome clinic each having one promotora with 20 intervention patient cohorts beginning on April 1, 2015. Because each of these clinics is smaller than Caldwell, three cycles (instead of four) of three month intense promotora exposure (4 individual and 4 group sessions) will be held and fewer patients will be recruited. Of course, each 20 person cohort will be mirrored by a 20 patient control group. Again after the intense promotora exposure, all intervention patients will experience once monthly large group sessions with a promotora and will complete qualitative questionnaires and laboratory tests at six month intervals until one year from their start date arrives.

For all clinics, patients assigned to the control group will have an entrance physical screening and complete their qualitative questionnaires and PAM instrument and have laboratory tests at the start of the study, at six month intervals, and an exit physical exam one year after enrolling in the study.

Promotoras will be recruited from each community with significant input from members of the Hispanic Community Advisory Board (CAB) that has been actively involved in the Companeros en Salud (CES) or Partners in Health (PIH) program through the Idaho Partnership for Hispanic Health for the past five years. The promotora training model for this study is adapted from the established curriculum for that project. Standard templates for recruitment and training have been developed by Linda Powell, Principal Investigator of the Companeros en Salud project. Co-PI Lynda Bennett of Mountain States Group will direct the recruitment, training and ongoing support/oversight of promotoras to ensure consistency of delivery of intervention trainings across the three communities, as well as timeliness and fidelity to the topics they are to discuss with group members and their families.

• Study Type: Interventional
• Phase: Not Applicable

Contacts and Locations

Study Locations

• United States
  • Idaho
    • Caldwell, Idaho, United States, 83605
      • Saint Alphonsus Medical Group Caldwell Clinic
    • Jerome, Idaho, United States, 83338
      • Saint Lukes Clinic Jerome
    • Nampa, Idaho, United States, 83686
      • St Alphonsus Medical Group Nampa Clinic

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 18 years and older (Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Adult
• Rural dwelling Hispanics who have been diagnosed with metabolic syndrome

Exclusion Criteria:

• All others

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: Triple

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Promotora plus standard care model; Promotora plus standard physical screening exam, hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count	Behavioral: Promotora plus standard physical screening exam , hemoglobin A1c levels, lipid panels, fasting glucose, height, weight, BMI, Complete Blood Count; Promotora services plus the standard care model will be provided for one randomly assigned cohort of patients meeting the inclusion criteria while the other cohort will receive the standard care model only

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Change in Patient Activation Measure from baseline to six months and six months to one year	The patient activation measure (PAM), developed by Hibbard and colleagues, measures patient activation, which has been described as involving four sequential stages: 1) patients believe they have an important role in managing their health, 2) patients possess the necessary knowledge to manage their health, 3) patients take both behavioral and skill-based action to maintain their health, and 4) patients manage their health as best possible under most any circumstance or change in health condition.22 It consists of a 13 item questionnaire which asks respondents to answer "strongly agree", "agree", "disagree" or "strongly disagree" to each item. Scores indicate which of the four stages the respondent is in.	study entry, six months, one year

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in patient attitudes about providers and carefrom baseline to six months and six months to one year	An attitudinal qualitative measures instrument has been derived from a variety of studies, instruments, and theories. The instrument, which features a series of directional attitude statements, consists of 23 statements all of which have Likert Scale response categories "strongly agree", "agree", "disagree", "strongly disagree", and "have not considered". Each of the perspectives/attitudes patients and providers planning this study desired to be measured is reflected in the instrument, i.e., trust in medical providers and the health care system, attitudes about procedural fairness in health care treatment, comfort with seeking care in the health care system, attitudes about communication patterns between physicians and patients, and potential feelings of cultural treatment bias against minorities. The statements are scrambled so that respondents will not pick up a pattern, and attitude perception scores are tallied by combining scores from like items.	study entry, six months, and one year

Other Outcome Measures

Outcome Measure	Measure Description	Time Frame
Changes in sequelae associated with metabolic syndrome from baseline to six months and six months to one year	A reduction in sequelae associated with metabolic syndrome; Fewer patients will become diabetic; Fewer heart attacks and strokes	study entry, six month and one year

Collaborators and Investigators

• Sponsor: Family Medicine Residency of Idaho
• Collaborators: Saint Alphonsus Medical Group; Mountain States Group; Quantified, Inc.
• Investigators: Principal Investigator: James T Girvan, PhD, MPH, Family Medicine Residency of Idaho; Study Director: James Gardner, MD, Saint Aphonsus Medical Group and Family Medicine Residency of Idaho Rural Training Track Director; Study Chair: Ted Epperly, MD, Family Medicine Residency of Idaho

Study record dates

Study Major Dates

• Study Start: September 1, 2013
• Primary Completion (Anticipated): June 1, 2016
• Study Completion (Anticipated): August 1, 2016

Study Registration Dates

• First Submitted: April 18, 2013
• First Submitted That Met QC Criteria: April 22, 2013
• First Posted (Estimate): April 25, 2013

Study Record Updates

• Last Update Posted (Actual): February 14, 2017
• Last Update Submitted That Met QC Criteria: February 13, 2017
• Last Verified: February 1, 2017

More Information

Terms related to this study

• Keywords: metabolic syndrome; rural; Promotoras; Hispanic Adults; patient attitudes; provider cultural competency; patient activation measure
• Additional Relevant MeSH Terms: Pathologic Processes; Glucose Metabolism Disorders; Metabolic Diseases; Disease; Insulin Resistance; Hyperinsulinism; Syndrome; Metabolic Syndrome; Physiological Effects of Drugs; Peripheral Nervous System Agents; Analgesics; Sensory System Agents; Anti-Inflammatory Agents, Non-Steroidal; Analgesics, Non-Narcotic; Anti-Inflammatory Agents; Antirheumatic Agents; Chrysarobin
• Other Study ID Numbers: FMRI Promotora Trial

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO
• IPD Plan Description: No plan to share IPD as funding for the study was not successful so no recruiting occurred, thus, no IPD.